Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disorders Centessa’s OX2R agonist pip...
Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics’ geographical diversific...
4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces a significant expansio...
Company has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway Company plans to submit...
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation c...
Stratum Biosciences, a biotechnology pioneer at the intersection of artificial intelligence and dermatology research, announced the closing of a $2...
Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA...
SK pharmteco, a leading global contract development and manufacturing organization (CDMO), and Prozomix, a pioneer in enzyme discovery and diversity,...
Gilead Sciences, Inc. (Nasdaq: GILD) announced it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology...
New “Danaher Beacon,” first in the European Union, aims to accelerate translation, scalability, and reliability across cell and gene therap...
For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrut...
While companies make decarbonization progress elsewhere, heat has been considered too challenging to progress. - ...
First study to demonstrate safe and selective administration of sustained and localized delivery of enzalutamide -Alessa Therapeutics (“...
- Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study - The enhanced immunosu...
© 2026 Biopharma Boardroom. All Rights Reserved.
